Enter Your Search:
Results 1-2 (2)
Go to page number:
Select a Filter Below
Progress in brain research (1)
The European journal of neuroscience (1)
Soderstrom, Katherine E. (2)
Collier, Timothy J. (1)
Kordower, Jeffrey H. (1)
Levine, Nathan D. (1)
O’Malley, Jennifer A. (1)
Ramaswamy, Shilpa (1)
Sortwell, Caryl E. (1)
Steece-Collier, Kathy (1)
Year of Publication
Did you mean:
author:("fagerstrom, Katherine E.")
Trophic factors therapy in Parkinson’s disease
Kordower, Jeffrey H.
Progress in brain research
Parkinson’s disease (PD) is a progressive, neurodegenerative disorder for which there is currently no effective neuroprotective therapy. Patients are typically treated with a combination of drug therapies and/or receive deep brain stimulation to combat behavioral symptoms. The ideal candidate therapy would be the one which prevents neurodegeneration in the brain, thereby halting the progression of debilitating disease symptoms. Neurotrophic factors have been in the forefront of PD research, and clinical trials have been initiated using members of the GDNF family of ligands (GFLs). GFLs have been shown to be trophic to ventral mesencephalic cells, thereby making them good candidates for PD research. This paper examines the use of GDNF and neurturin, two members of the GFL, in both animal models of PD and clinical trials.
neurotrophic factors; Parkinson’s disease; glial cell line-derived neurotrophic factor family ligands; GDNF; neurturin; gene therapy; clinical trials
Impact of Dendritic Spine Preservation in Medium Spiny Neurons on Dopamine Graft Efficacy and the Expression of Dyskinesias in Parkinsonian Rats
O’Malley, Jennifer A.
Levine, Nathan D.
Sortwell, Caryl E.
Collier, Timothy J.
The European journal of neuroscience
Dopamine deficiency associated with Parkinson’s disease (PD) results in numerous changes in striatal transmitter function and neuron morphology. Specifically, there is marked atrophy of dendrites and dendritic spines on striatal medium spiny neurons (MSN), primary targets of inputs from nigral dopamine and cortical glutamate neurons, in advanced PD and rodent models of severe dopamine depletion. Dendritic spine loss occurs via dysregulation of intraspine Cav1.3 L-type Ca2+ channels and can be prevented, in animal models, by administration of the calcium channel antagonist, nimodipine. The impact of MSN dendritic spine loss in the parkinsonian striatum on dopamine neuron graft therapy remains unexamined. Using unilaterally parkinsonian Sprague Dawley rats, we tested the hypothesis that MSN dendritic spine preservation through administration of nimodipine would result in improved therapeutic benefit and diminished graft-induced behavioral abnormalities in rats grafted with embryonic ventral midbrain cells. Analysis of rotational asymmetry and spontaneous forelimb use in the cylinder task found no significant effect of dendritic spine preservation in grafted rats. However, analyses of vibrissae-induced forelimb use, levodopa-induced dyskinesias, and graft-induced dyskinesias showed significant improvement in rats with dopamine grafts associated with preserved striatal dendritic spine density. Nimodipine treatment in this model did not impact dopamine graft survival but allowed for increased graft reinnervation of striatum. Taken together, these results demonstrate that even with grafting suboptimal numbers of cells, maintaining normal spine density on target MSNs results in overall superior behavioral efficacy of dopamine grafts.
dyskinesia; Parkinson’s disease; nimodipine; transplantation; medium spiny neuron
Results 1-2 (2)
Go to page number:
Remove citation from clipboard
Add citation to clipboard
This will clear all selections from your clipboard. Do you wish proceed?
Clipboard is full! Please remove an item and try again.
PubMed Central Canada is a service of the
Canadian Institutes of Health Research
(CIHR) working in partnership with the National Research Council's
national science library
in cooperation with the
National Center for Biotechnology Information
U.S. National Library of Medicine
(NCBI/NLM). It includes content provided to the
PubMed Central International archive
by participating publishers.